Literature DB >> 25680872

Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.

Aaron Goldberg1, Richard D Gerkin, Michele Young.   

Abstract

BACKGROUND: Barrett's esophagus (BE) is a complication of gastroesophageal reflux disease (GERD) that is a precursor to esophageal adenocarcinoma. There is limited information regarding whether medications can reduce the risk of developing BE. AIM: We analyzed medical records at a large veterans hospital to determine the effects of statins, aspirin, non-aspirin NSAIDs, calcium, or multivitamins on the risk of developing BE.
METHODS: In this retrospective case-control study, 250 patients with biopsy-confirmed Barrett's esophagus were compared with 250 controls with acid-peptic symptoms but no endoscopic BE. Medication histories were reviewed for the use of the above substances prior to endoscopic evaluation. Logistic and linear regression was used to determine predictors of the outcomes.
RESULTS: Mean age at diagnosis was significantly older in the Barrett's population compared with controls (61.2 vs. 56.7 years, P < 0.001), with no difference in mean BMI (29.1 vs. 29.0, respectively). On multivariate analysis, independently significant factors for risk of BE were found with multivitamins (OR 0.41, P = 0.001), statins (OR 0.53, P = 0.003), age (OR 1.033/year, P = 0.001), and Hispanic ethnicity (OR 0.38, P = 0.007). Furthermore, statin use was associated with less long-segment (3 cm or longer) BE and was inversely correlated with continuous BE length.
CONCLUSIONS: GERD patients with BE are less likely to use multivitamins and statins, as well as less likely to be of Hispanic ethnicity. Additionally, statins were inversely associated with BE length. Prospective studies of this topic are indicated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25680872     DOI: 10.1007/s10620-015-3569-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

2.  Statin use is associated with a decreased risk of Barrett's esophagus.

Authors:  Theresa Nguyen; Natalia Khalaf; David Ramsey; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2014-05-02       Impact factor: 22.682

3.  Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.

Authors:  Romy E Verbeek; Max Leenders; Fiebo J W Ten Kate; Richard van Hillegersberg; Frank P Vleggaar; Jantine W P M van Baal; Martijn G H van Oijen; Peter D Siersema
Journal:  Am J Gastroenterol       Date:  2014-07-01       Impact factor: 10.864

4.  Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Authors:  Florine Kastelein; Manon C W Spaander; Katharina Biermann; Ewout W Steyerberg; Ernst J Kuipers; Marco J Bruno
Journal:  Gastroenterology       Date:  2011-08-28       Impact factor: 22.682

Review 5.  Calcium phosphate, bile acids and colorectal cancer.

Authors:  R Van der Meer; J H Kleibeuker; J A Lapré
Journal:  Eur J Cancer Prev       Date:  1991-10       Impact factor: 2.497

6.  Screening for Barrett's esophagus in colonoscopy patients with and without heartburn.

Authors:  Douglas K Rex; Oscar W Cummings; Michael Shaw; Mark D Cumings; Roy K H Wong; Raj S Vasudeva; Donal Dunne; Emad Y Rahmani; Debra J Helper
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

7.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

Review 8.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.

Authors:  Douglas A Corley; Karla Kerlikowske; Rajiv Verma; Patricia Buffler
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

9.  Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Authors:  Howard D Sesso; William G Christen; Vadim Bubes; Joanne P Smith; Jean MacFadyen; Miriam Schvartz; JoAnn E Manson; Robert J Glynn; Julie E Buring; J Michael Gaziano
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

10.  Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.

Authors:  Ian L P Beales; Inna Vardi; Leanne Dearman
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 2.566

View more
  5 in total

1.  Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.

Authors:  Ian L P Beales; Leanne Dearman; Inna Vardi; Yoon Loke
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

2.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

3.  The frequency of histologically confirmed Barrett's esophagus varies by the combination of ethnicity and gender.

Authors:  Sian S Chisholm; Joe E Khoury; M Mazen Jamal; Carlos Palacio; Sunitha Pudhota; Kenneth J Vega
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 4.  Metabolic syndrome is associated with increased risk of Barrett esophagus: A meta-analysis.

Authors:  Qiong He; Jian-Dong Li; Wei Huang; Wen-Chang Zhu; Jian-Quan Yang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

5.  Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.

Authors:  Zhanwei Zhao; Zifang Yin; Chaojun Zhang
Journal:  Cancer Med       Date:  2021-06-15       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.